The reverse merger transforms MGRX from a men's health company into a publicly traded advanced nuclear microreactor developer with a $15M PIPE. Monitor for stockholder and Nasdaq approvals, which are required to unlock full economic rights. The deal structure suggests a high probability of completion given the minimum PIPE condition and voting support agreements covering ~50.1% of shares. Post-closing, focus on Nuclea's regulatory and commercialization milestones for the Morpheus reactor.
Price Chart
Executive Summary
Mangoceuticals (MGRX) has entered into a definitive business combination agreement with Nuclea Energy Inc., a development-stage advanced nuclear microreactor company. Under the terms, Nuclea shareholders will receive exchangeable shares convertible into Mango common stock, representing approximately 96% of the combined entity's fully diluted equity (pre-PIPE), while existing Mango shareholders are diluted to ~4%. The transaction includes a concurrent minimum $15.0M PIPE financing and is structured as a two-stage closing, with the initial closing expected before required stockholder and Nasdaq approvals. The filing also reflects the departure of CEO Jacob D. Cohen (who becomes President with a $1.5M cash severance, 2M bonus shares, and a $10M warrant in a subsidiary), a reduction in the stockholder meeting quorum to 33.33%, and grants of 400,000 fully vested shares to directors and CFO.
Key Financial Metrics
Key Facts
- Nuclea shareholders receive ~96% of Mango on a fully diluted as-exchanged basis (pre-PIPE); existing Mango shareholders retain ~4%.
- Minimum $15,000,000 PIPE financing is a condition to closing.
- Exchangeable shares are exchangeable 1:1 for Mango common stock, subject to a 19.99% Nasdaq Cap until Required Approvals are obtained.
- CEO Jacob D. Cohen steps down at closing, receives $1,500,000 cash severance, 2,000,000 bonus shares, and a $10,000,000 cashless warrant in Mango & Peaches Corp.
- Bylaw quorum requirement reduced from a majority to 33.33% of voting power to facilitate stockholder approval.
- 400,000 fully vested shares granted to directors and CFO (100,000 each) on July 28, 2026.
- Transaction requires Mango stockholder approval, Nasdaq initial listing approval, and regulatory clearances under Investment Canada Act, Competition Act, and HSR.
- Closing expected before Required Approvals; Completion (full rights) occurs after approvals.
Financial Impact
Existing Mango shareholders diluted from 100% to ~4% ownership; combined entity capitalized with at least $15M PIPE; severance and warrant obligations total $1.5M cash + 2M shares + $10M warrant (valued at issuance).
Risk Factors
- Failure to obtain Mango stockholder approval or Nasdaq initial listing approval would halt the transaction.
- Development-stage nuclear technology carries significant regulatory, technical, and commercialization risks.
- Existing Mango shareholders face extreme dilution (to ~4% ownership).
- Nasdaq compliance risk: Mango needs a second 180-day grace period for minimum bid price by August 3, 2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-035323 |
| Exhibit: ex10-1.htm | 0001493152-26-035323 |
| Exhibit: ex99-1.htm | 0001493152-26-035323 |
| Exhibit: ex3-1.htm | 0001493152-26-035323 |
| Document: form8-k.htm | 0001493152-26-035323 |
| Document: 0001493152-26-035323-index-headers.html | 0001493152-26-035323 |
| Document: 0001493152-26-035323-index.html | 0001493152-26-035323 |
| Document: 0001493152-26-035323.txt | 0001493152-26-035323 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $0.3834 $0.2801 | ▲ +26.94% | ▲ +25.45% | $0.2480 (+35.32%) |
Oct 9, 2026 18d ago | 424B5 | $0.3834 $0.2801 | ▲ +26.94% | ▲ +25.45% | $0.2480 (+35.32%) |
Oct 6, 2026 21d ago | SC 13D/A | $0.4500 $0.3716 | ▼ −17.42% | ▼ −17.28% | $0.2480 (−44.89%) |
Oct 1, 2026 26d ago | 8-K | $0.4805 $0.4324 | ▼ −10.01% | ▼ −11.31% | $0.2480 (−48.39%) |
Jul 30, 2026 12w ago | 425 | $0.2936 $0.5270 | ▲ +79.50% | ▲ +75.87% | $0.2480 (−15.53%) |
Jul 30, 2026 12w ago | 8-K | $0.2936 $0.5270 | ▲ +79.50% | ▲ +75.87% | $0.2480 (−15.53%) |
Mar 6, 2026 33w ago | Press Release | $0.3470 $0.4040 | ▲ +16.43% | ▲ +17.78% | $0.2480 (−28.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers